Kano Therapeutics

Exactly two years ago on September 6th I joined Kano! We like to joke about me being the first employee but it has been so special to see everything and everyone, especially myself, grow! So of course I wanted to be silly and wear the same outfit that I did on my first day and get another group photo. Thank you Floris Engelhardt and John Vroom for these very special two years that I get to look back on as I continue working alongside every amazing person here, and also for suggesting to take a picture on the skybridge (I am afraid of heights).

"Secured an oversubscribed $5 million seed round.?The Engine Ventures?and?Vsquared Ventures?co-led the round, with?Taihill Venture?and?Metaplanet?also participating. The round brings Kano’s total funding to date to $7.1 million." https://lnkd.in/efiqwCzj We are absolutely thrilled to be working with Engine Ventures, Amino Collective, Vsquared Ventures, Metaplanet, and Taihill Venture. Also included in our gratitude must be Jacob Becraft, Jacob Corn, Brian Shy, and Stephen Sofen. Thanks to Walker Comms for working with us on this announcement.

In 2021, during the Nucleate Activator program, I first discovered Endpoints News — proof of how new I was to biopharma! Now, after being a subscriber for three years, I have the opportunity to share this article with you, written by the phenomenal Ryan Cross. https://lnkd.in/ePnx9TfD I need thank my co-founders John Vroom, Mark Bathe and some special organizations that have guided me from coming to the US in 2020 to leading an organization with the most fantastic scientists and developing therapeutic opportunities for gene insertions at Kano Therapeutics. Massachusetts Institute of Technology, UMass Boston, Activate, The Termeer Foundation, The Engine, Engine Ventures, Vsquared Ventures, Amino Collective, Metaplanet, Taihill Venture

Explore our newest roles and join a team that's at the forefront of scientific innovation: ???Senior Scientist, Downstream Process Development & Analytics ???Apply Now: https://lnkd.in/eBusJGPB ???Sr. Research Associate/Scientist, Mammalian Cell Genome Editing ???Apply Now: https://lnkd.in/ecJrDsZE Discover more about our career opportunities and how you can make an impact: ???https://lnkd.in/e7fVWf2e

We are thrilled to announce that we’ve been selected as a spoke of the Advanced Research Projects Agency for Health (ARPA-H) Investor Catalyst Hub network!?We are excited to contribute to the community.

We're hiring! Kano is seeking a discovery research scientist to help bring our early pipeline programs closer to patients. If you're interested in joining our team apply here: https://lnkd.in/dSK-YXiQ

Welcome on board! We’re incredibly excited to have you join the team.

Kano seeks a hands-on discovery research leader to play a critical role in the development of our preclinical research function. You want to manage internal discovery and validation R&D projects and lead Kano’s internal and external program-specific research activities, including validating and de-risking lead candidates? Apply here: https://lnkd.in/detAbT-x

Today, we announce the formation of our Scientific Advisory Board with globally recognized leaders in nucleic acid therapeutics and genome editing. Thanks to Dr. Stephen Sofen, Prof. Brian Shy, and Prof. Jacob Corn for joining our mission to enable the next generation of genetic medicines through DNA payload innovation. Sincerely, Kano’s founders Floris Engelhardt, John Vroom, and Mark Bathe